Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin.
18 affiliations
- 1Department of Neurology, Institut Català d'Oncologia-Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain. [email protected].
- 2Department of Cell Biology, Physiology and Immunology, Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Universitat Autònoma de Barcelona, Bellaterra, Spain. [email protected].
- 3University of Sao Paulo Medical School, Sao Paulo, Brazil.
- 4Agios Andreas General Hospital of Patras, Patras, Greece.
- 5Università Di Milano-Bicocca, Monza, Italy.
- 6Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
- 7Institut Catala d'Oncologia, Hospital Duran Reynals Barcelona, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
- 8Oslo University Hospital, Oslo, Norway.
- 9Clínica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
- 10University Costa del Sol Hospital Marbella, Málaga, Spain.
- 11School of Psychology, Health & Clinical Sciences at, Aston University, Birmingham, UK.
- 12University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense, Madrid, Spain.
- 13Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
- 14University of Birmingham, Birmingham, UK.
- 15Guy's and St Thomas' NHS Foundation Trust, London, UK.
- 16School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong.
- 17Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
- 18Epworth Healthcare, Victoria, Australia.
Abstract
Purpose
Brentuximab vedotin (BV) represents a therapeutic advancement in the treatment of CD30-positive lymphomas, yet its clinical utility is often limited by BV-induced peripheral neuropathy (PN). Currently, evidence-based, BV-specific guidelines for the assessment and management of PN are scarce, resulting in variability in clinical practice. This study aimed to establish international expert consensus on the optimal assessment, monitoring and management strategies for BV-induced PN in patients with lymphoma.Methods
A modified Delphi panel was conducted, engaging a total of 13 experts from eight different countries and representing haematology, neurology, dermatology, nursing and allied health disciplines. Panellists participated in three rounds of structured surveys, with statements developed based on a targeted literature review and guidance from an expert steering committee. Consensus was defined as ≥ 70% agreement/disagreement. Consensus was achieved on 60/87 (69%) statements across domains including risk factor assessment, symptom monitoring, pharmaceutical and non-pharmaceutical management.Results
Key recommendations include routine risk profiling before BV initiation, use of validated assessment tools at baseline and throughout therapy, multidisciplinary collaboration, and early intervention for worsening PN. Areas of uncertainty and variability in PN management remain, particularly regarding management of intermediate-grade PN and optimal non-pharmacological strategies.Conclusion
These international consensus recommendations provide practical guidance for improving clinical management of BV-induced PN and highlight the importance of early identification, personalised care and multidisciplinary collaboration. Further research is needed to address persistent gaps and inform future clinical guidelines.
Related
- "It's Like a Marathon": A Qualitative Study of Symptom Burden and Adaptation Among Patients with Oxaliplatin-Induced Peripheral Neuropathy During Treatment.
- Effect of cryotherapy on chemotherapy-induced peripheral neuropathy in patients with breast cancer treated with taxanes: a systematic review using the GRADE system.
- Risk factors for diabetic peripheral neuropathy in diabetes mellitus patients: A case-control study.
- Impact of neuropathy severity on hand function, strength, and dexterity in patients with oxaliplatin-induced peripheral neuropathy.
- Quality-of-Life Changes Following Cisplatin-Based Chemotherapy in Patients with Lung Cancer and Cisplatin-Induced Peripheral Neuropathy: A Sex-Stratified Analysis
BibTeX
@article{velasco2026expert,
title = {{Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin.}},
author = {Roser Velasco and José A Sanches and Andreas A Argyriou and Guido Cavaletti and Eva Domingo-Domenech and Alexander Fosså and Jaime Gállego Pérez-Larraya and Antonia Miranda Ruiz and Alex Molassiotis and André Neder Ramires Abdo and Pablo L Ortiz-Romero and Susanna B Park and Julia Scarisbrick and Lauren Urwin and Mian Wang and H Miles Prince},
journal = {Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer},
year = {2026},
month = oct,
doi = {10.1007/s00520-026-11314-5},
url = {https://europepmc.org/article/MED/42891686},
note = {CC BY},
}
RIS
TY - JOUR
TI - Expert consensus on the management of peripheral neuropathy in patients with lymphoma on brentuximab vedotin.
AU - Roser Velasco
AU - José A Sanches
AU - Andreas A Argyriou
AU - Guido Cavaletti
AU - Eva Domingo-Domenech
AU - Alexander Fosså
AU - Jaime Gállego Pérez-Larraya
AU - Antonia Miranda Ruiz
AU - Alex Molassiotis
AU - André Neder Ramires Abdo
AU - Pablo L Ortiz-Romero
AU - Susanna B Park
AU - Julia Scarisbrick
AU - Lauren Urwin
AU - Mian Wang
AU - H Miles Prince
PY - 2026
DA - 2026/10/17
JO - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
DO - 10.1007/s00520-026-11314-5
UR - https://europepmc.org/article/MED/42891686
AB - Purpose Brentuximab vedotin (BV) represents a therapeutic advancement in the treatment of CD30-positive lymphomas, yet its clinical utility is often limited by BV-induced peripheral neuropathy (PN). Currently, evidence-based, BV-specific guidelines for the assessment and management of PN are scarce, resulting in variability in clinical practice. This study aimed to establish international expert consensus on the optimal assessment, monitoring and management strategies for BV-induced PN in patients with lymphoma.Methods A modified Delphi panel was conducted, engaging a total of 13 experts from eight different countries and representing haematology, neurology, dermatology, nursing and allied health disciplines. Panellists participated in three rounds of structured surveys, with statements developed based on a targeted literature review and guidance from an expert steering committee. Consensus was defined as ≥ 70% agreement/disagreement. Consensus was achieved on 60/87 (69%) statements across domains including risk factor assessment, symptom monitoring, pharmaceutical and non-pharmaceutical management.Results Key recommendations include routine risk profiling before BV initiation, use of validated assessment tools at baseline and throughout therapy, multidisciplinary collaboration, and early intervention for worsening PN. Areas of uncertainty and variability in PN management remain, particularly regarding management of intermediate-grade PN and optimal non-pharmacological strategies.Conclusion These international consensus recommendations provide practical guidance for improving clinical management of BV-induced PN and highlight the importance of early identification, personalised care and multidisciplinary collaboration. Further research is needed to address persistent gaps and inform future clinical guidelines.
SN - 0941-4355
SN - 1433-7339
ER -